Product Images Besponsa

This is a survival analysis study comparing two treatments, BESPONSA and Investigator's Choice of Chemotherapy. The survival probability and hazard ratio are reported. The number of patients at risk is shown for each treatment arm over time. The median survival time was 7.7 months for BESPONSA and 6.2 months for Investigator's Choice of Chemotherapy. The hazard ratio was 0.75 with a 97.5% confidence interval [0.57-0.99].*

This is a description indicating that a company called Wyeth Pharmaceuticals LLC manufactured a product. It is mentioned that the company is a subsidiary of Pfizer Inc in Philadelphia with postcode 19101.*

NE @ NDC 0008-0100-01 is a refrigerated vial, which should be stored at a temperature between 2°C to 8°C (36°F to 46°F), in its original carton to protect it from light. It is prescribed for the treatment of Inotuzumab Ozogamicin. The medication should not be frozen and instructions for preparation and administration can be found in the prescribing information. The concentration of the injection is 0.25 mg/mL when reconstituted with 4mL sterile water for injection. The medication is manufactured by Wyeth Pharmaceuticals LLC and is for intravenous infusion only. Discard unused portion.*

BESPONSA is a prescription medication in the form of an injection used as a treatment for certain types of Leukemia. The medication comes in the form of single-dose vials each containing 0.9mg/vial of inotuzumab ozogamicin. The vials need to be refrigerated at 2°C to 8°C and should be discarded after use. One should not use the medication if it contains any visible particles or discoloration. The medication should only be used under a physician's supervision.*